

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/590,675	
			Filing Date	October 18, 2007	
			First Named Inventor	Nasser Chegini	
			Group Art Unit	1645	
			Examiner Name		
			Attorney Docket Number	UF.418C2XCZ1	
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	CHEGINI, N. "Implication of growth factor and cytokine networks in leiomyomas" In Cytokines in human reproduction. J. Hill ed. New York, Wiley & Sons Publisher, 2000, 133-162.	
	R2	NOWAK "Fibroids: pathophysiology and current medical treatment" <i>Bailliere Best Pract Res. Clin Obstet. Gynaecol.</i> , 1999, pp. 223-238, Vol. 13.	
	R3	STEWART <i>et al.</i> , "Steroidal treatment of myomas: Preoperative and long-term medical therapy" <i>Semin. Reprod. Endocrinol.</i> , 1995, pp. 344-357, Vol. 10.	
	R4	TAKEUCHI <i>et al.</i> "A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis" <i>J Obstet Gynaecol Res</i> , 2000, pp. 325-331, Vol. 26.	
	R5	KLAUSEN <i>et al.</i> Multiplicity of gonadotropin-releasing hormone signaling: a comparative perspective" <i>Prog Brain Res</i> , 2002, pp. 111-128, Vol. 141, abstract.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.